Opinion

Video

Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC

Author(s):

Benjamin Garmezy, MD,Martin H. Voss, MD

Medical oncologists provide clinical insights on managing adverse events associated with IO-TKI and IO-IO regimens in patients with advanced renal cell carcinoma.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!

Latest CME

View All
(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments
Video

(CME Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2
Video

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

Apr 23rd 2025 - Apr 24th 2026

online-activity
View More
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
View More
Related Content
Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
April 25th 2025

Oncology Experts Preview Abstracts to Watch at the 2025 AACR Annual Meeting

Daniel P. Petrylak, MD, professor, medicine (medical oncology) and urology, chief, Genitourinary Oncology, Yale School of Medicine and Smilow Cancer Hospital
April 24th 2025

Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD

Isabel Preeshagul, DO, MBS
April 18th 2025

Tarlatamab and Durvalumab Enhance the SCLC Immunotherapy Paradigm

Ramez N. Eskander, MD, gynecologic oncologist, assistant professor, obstetrics, gynecology, and reproductive sciences, the University of California San Diego Health; Rachel N. Grisham, MD, associate attending physician, Memorial Sloan Kettering Cancer Center; Benjamin Herzberg, MD, assistant professor, medicine, Columbia University Medical Center, oncologist, Herbert Irving Comprehensive Cancer Center; Kelly McCann, MD, PhD, assistant professor, breast medical oncologist, UCLA Health’s David Geffen School of Medicine; Gregory Roloff, MD, hematologist/oncologist, the University of Chicago Medicine
March 31st 2025

Oncology Experts Discuss the Long-Term Effects of the COVID-19 Pandemic: With Ramez N. Eskander, MD; Rachel N. Grisham, MD; Benjamin Herzberg, MD; Kelly McCann, MD, PhD; and Gregory Roloff, MD

Marc R. Matrana, MD
April 16th 2025

RCC Treatment Decision-Making Requires a Balance of Efficacy and Individual Patient Considerations

D-VRd in Multiple Myeloma | Image Credit: © ChaoticMind – stock.adobe.com
April 13th 2025

CEPHEUS Data Support D-VRd in Transplant-Ineligible or -Deferred Patients With Myeloma Who Can Tolerate Bortezomib